Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Express Scripts
Baxter
McKinsey
Merck

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 6,528,313

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,528,313
Title: Procedure for specific replacement of a copy of a gene present in the recipient genome by the integration of a gene different from that where the integration is made
Abstract:The present invention relates to a process for targeted replacement of at least a part of an endogenous gene by at least a part of a foreign gene or targeted insertion of at least a part of a foreign gene at a targeted site in an endogenous gene in a cell by homologous recombination. This process includes (A) providing a vector which contains (1) at least a part of the foreign gene which is heterologous with respect to the endogenous gene; (2) a first flanking DNA sequence homologous to a first genomic sequence situated on one side of the part of the endogenous gene to be replaced or the targeted site; and (3) a second flanking DNA sequence homologous to a second genomic sequence situated on the other side of the part of the endogenous gene to be replaced or the targeted site, the foreign gene being located between the first and second flanking DNA sequences and is complementary to the part of the endogenous gene to be replaced; (B) transfecting a cell with the vector; (C) and selecting a transfected cell that contains the foreign gene at the targeted site or where the part of the endogenous gene is to be replaced.
Inventor(s): Le Mouellic; Herve (Paris, FR), Brulet; Philippe (Maurepas, FR)
Assignee: Institut Pasteur (Paris, FR)
Application Number:08/301,037
Patent Claims:1. An in vitro process for providing a recombinant, heterologous gene in a genome of a mammalian cell, wherein the process comprises: (A) providing a mammalian cell having a recipient gone in its genome, wherein said recipient gene comprises complementing DNA comprising a first nucleotide sequence and a second nucleotide sequence downstream of said first nucleotide sequence; (B) transfecting said mammalian cell in vitro with a DNA comprising: (1) a third nucleotide sequence homologous to said first nucleotide sequence; (2) a fourth nucleotide sequence homologous to said second nucleotide sequence; and (3) a DNA sequence heterologous with respect to DNA in said recipient gene, wherein said heterologous DNA sequence is between said third and said fourth nucleotide sequences and said heterologous DNA sequence comprises a first insertion DNA sequence and a second insertion DNA sequence, wherein said first insertion DNA sequence comprises a first coding sequence that encodes a first product that does not confer resistance to a selection agent involved in the selection of transformants, and said second insertion DNA sequence comprises a second coding sequence that encodes a second product that confers resistance to a selection agent involved in the selection of transformants, and a promoter allowing the expression of said second product in said mammalian cell; and (C) selecting a transfected cell in which said heterologous DNA sequence has been inserted between said first and said second nucleotide sequences in said recipient gene by homologous recombination with said third and said fourth nucleotide sequences to thereby provide a mammalian cell containing in its genome the recombinant, heterologous gene, and in addition, the second insertion DNA sequence encoding the selective agent.

2. The in vitro process as claimed in claim 1, wherein insertion of said heterologous DNA in said recipient gene is accompanied by replacement of recipient gene DNA.

3. The in vitro process as claimed in claim 1, wherein said recipient gene contains a promoter, which is inactivated following insertion of said heterologous DNA sequence into said recipient gene.

4. The in vitro process as claimed in claim 1, wherein said recipient gene has a regulatory sequence and said coding sequence of said first insertion DNA sequence is under the control of said regulatory sequence following insertion of said heterologous DNA sequence into said recipient gene.

5. The in vitro process as claimed in claim 1, wherein each of said third and said fourth nucleotide sequences has a length greater than 150 base pairs and shorter than the length of said recipient gene.

6. The in vitro process as claimed in claim 1, wherein said recipient gene is present in said mammalian cell in at least two copies and said heterologous DNA sequence is inserted into only one copy of said recipient gene.

7. The in vitro process as claimed in claim 1, wherein said first coding sequence encodes an interferon, an interleukin, a .beta.-3-adrenergic receptor, a retinoic acid receptor, an HIV receptor, or lac Z.

8. The in vitro process as claimed in claim 1, wherein said first coding sequence encodes lac Z.

9. The in vitro process as claimed in claim 1, wherein said mammalian cell is a mouse embryonic stem (E. S.) cell.

10. The in vitro process as claimed in claim 1, wherein said transfection is by electroporation.

11. The in vitro process as claimed in claim 1, which further comprises amplifing by polymerase chain reaction the heterologous DNA sequence at the locus at which the insertion is made.

12. The in vitro process as claimed in claim 1, wherein the selective agent is neoR.

13. The in vitro process as claimed in claim 1, wherein said recipient gene codes for a receptor for an infectious agent, said recipient gene is present in said mammalian cell in at least two copies, and said heterologous DNA sequence is inserted into only one copy of said recipient gene.

14. Mammalian cells transformed according to the in vitro process of claim 1.

15. Mammalian cells according to claim 14, wherein said mammalian cells comprise mouse embryonic stem (E. S.) cells.

16. The in vitro process as claimed in claim 1, wherein said recipient gene is not expressed in said mammalian cell and expression of said recipient gene is made possible following insertion of said heterologous DNA sequence in said recipient gene.

17. Mammalian cells transformed according to the in vitro process of claim 16.

18. Mammalian cells according to claim 17, wherein said mammalian cells comprise mouse embryonic stem (E. S.) cells.

19. The in vitro process as claimed in claim 1, wherein expression of said recipient gene is modified following insertion of said heterologous DNA sequence.

20. The in vitro process as claimed in claim 1, wherein said second insertion DNA sequence lacks a polyadenylation sequence and is operably linked at the 3' end to a 5' region on an intron containing a sequence that causes the selective degradation of transcripts of said heterologous DNA sequence.

21. The in vitro process as claimed in claim 20, wherein the process further comprises achieving a homologous recombination frequency ratio of at least 1 homologous recombination event per 900 random insertion events.

22. The in vitro process as claimed in claim 20, wherein the process further comprises achieving a homologous recombination frequency ratio of at least 1 homologous recombination event per 40 random insertion events.

23. The in vitro process as claimed in claim 1, wherein the process further comprises achieving a homologous recombination frequency ratio of at least 1 homologous recombination event per 900 random insertion events.

24. The in vitro process as claimed in claim 1, wherein the process further comprises achieving a homologous recombination frequency ratio of at least 1 homologous recombination event per 40 random insertion events.

25. A recombinant heterologous gene made according to the in

Details for Patent 6,528,313

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Try it Free 2020-03-04
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try it Free 2020-03-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Johnson and Johnson
Medtronic
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.